目的:评价平喘固本汤合补肺汤治疗COPD稳定期的临床疗效及其安全性。方法:运用计算机检索Web of Science、PubMed、Cochrane Library、维普数据库、中国知网、万方数据库,筛选平喘固本汤合补肺汤治疗COPD稳定期的RCT,并由2名成员按照为...目的:评价平喘固本汤合补肺汤治疗COPD稳定期的临床疗效及其安全性。方法:运用计算机检索Web of Science、PubMed、Cochrane Library、维普数据库、中国知网、万方数据库,筛选平喘固本汤合补肺汤治疗COPD稳定期的RCT,并由2名成员按照为本研究制定的纳排标准分别独立筛选文献,筛选后建立表格录入文献数据,制作质量评估表,采用RevMan 5.3软件进行数据分析。结果:总纳入13篇文献,样本量1184例,Meta分析后并提取数据。结论:研究平喘固本汤合补肺汤联合西医常规治疗慢阻肺,在提高疗效、改善肺功能、免疫水平方面具有明显优势,为进一步开展更高质量的RCT研究提供了可观依据。Objective: To evaluate the clinical efficacy and safety of Pingchuan Guben Decoction combined with Bufeitang in the treatment of stable COPD. Methods: Computerized searches were conducted in Web of Science, PubMed, Cochrane Library, VIP Database, CNKI, and Wanfang Database to screen RCTs on the treatment of stable COPD with Pingchuan Guben Decoction combined with Bufeitang. Two members independently screened the literature according to the inclusion and exclusion criteria formulated for this study. After screening, a table was established to enter the literature data, and a quality assessment table was made. Data analysis was performed using RevMan 5.3 software. Results: A total of 13 articles were included, with a sample size of 1184 cases. Meta-analysis was conducted, and data was extracted. Conclusion: The combination of Pingchuan Guben Decoction and Bufeitang with conventional Western medicine in the treatment of COPD has obvious advantages in improving efficacy, lung function, and immune levels, providing a reliable basis for further high-quality RCT research.展开更多
文摘目的:评价平喘固本汤合补肺汤治疗COPD稳定期的临床疗效及其安全性。方法:运用计算机检索Web of Science、PubMed、Cochrane Library、维普数据库、中国知网、万方数据库,筛选平喘固本汤合补肺汤治疗COPD稳定期的RCT,并由2名成员按照为本研究制定的纳排标准分别独立筛选文献,筛选后建立表格录入文献数据,制作质量评估表,采用RevMan 5.3软件进行数据分析。结果:总纳入13篇文献,样本量1184例,Meta分析后并提取数据。结论:研究平喘固本汤合补肺汤联合西医常规治疗慢阻肺,在提高疗效、改善肺功能、免疫水平方面具有明显优势,为进一步开展更高质量的RCT研究提供了可观依据。Objective: To evaluate the clinical efficacy and safety of Pingchuan Guben Decoction combined with Bufeitang in the treatment of stable COPD. Methods: Computerized searches were conducted in Web of Science, PubMed, Cochrane Library, VIP Database, CNKI, and Wanfang Database to screen RCTs on the treatment of stable COPD with Pingchuan Guben Decoction combined with Bufeitang. Two members independently screened the literature according to the inclusion and exclusion criteria formulated for this study. After screening, a table was established to enter the literature data, and a quality assessment table was made. Data analysis was performed using RevMan 5.3 software. Results: A total of 13 articles were included, with a sample size of 1184 cases. Meta-analysis was conducted, and data was extracted. Conclusion: The combination of Pingchuan Guben Decoction and Bufeitang with conventional Western medicine in the treatment of COPD has obvious advantages in improving efficacy, lung function, and immune levels, providing a reliable basis for further high-quality RCT research.
